Broad antiviral and anti-inflammatory efficacy of nafamostat against SARS-CoV-2 and seasonal coronaviruses in primary human bronchiolar epithelia.

Additionally, three other chemokines MCP1, CSF2 and Matrix Metallopeptidase 2 (MMP1), had diminished levels after nafamostat treatment but did not quite reach statistical significance ( P = 0.161, P = 0.061, and P = 0.232, respectively) (Figure 2 ).

also in 679 other papers

Interestingly, nafamostat inhibition was reduced in the TMPRSS2‐edited populations (very clear for one of the two tested donors), although the difference did not reach statistical significance ( P = 0.328) (Figure 4C ).

also in 111,027 other papers